



PATENT
Attorney Docket No. UCSD1480-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Hostetler et al.	Art Unit:	1615
Application No.:	10/770,885	Examiner:	Snigdha Maewall
Filed:	February 2, 2004	Conf No.:	1066
Title:	LIPID DRUG CONJUGATES FOR LOCAL THERAPY OF EYE DISEASES		

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. 1.97, enclosed are references relating to the above-identified application. For the convenience of the Examiner, these references are listed on the attached Form PTO-1449 and a copy of each is enclosed herewith.

It is respectfully requested that these references be considered in the examination of this application and their consideration be made of written record in the application file.

08/06/2007 TNGUYEN2 00000034 10770885

01 FC:1806

180.00 0P

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"EXPRESS MAIL" LABEL NUMBER **EV 876 963 479 US**

DATE OF DEPOSIT **August 1, 2007**

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

SARA HARE

(TYPED OR PRINTED NAME OF PERSON MAILING PAPER)

(SIGNATURE OF PERSON MAILING PAPER OR FEE)

In Re Application Of:

Hostetler et al.

Application No.: 10/770,885

Filed: February 2, 2004

Page 2


PATENT

Attorney Docket No.: UCSD1480-1

Check number 586557 in the amount of \$730.00 is enclosed as payment for the additional claims fees (\$550.00) and information disclosure statement fee (\$180.00). No other fee is deemed necessary with the filing of this response. However, if any additional fees are due, the Commissioner is hereby authorized to charge any fees, or make any credits, to Deposit Account No. 07-1896 referencing the above-identified attorney docket number. A copy of the Transmittal Sheet is enclosed.

Respectfully submitted,

Date: August 1, 2007



Victor Repkin

Attorney for Applicants

Reg. No. 45,039

Telephone: (858) 638-6664

Facsimile: (858) 677-1465


DLA PIPER US LLP

4365 Executive Drive, Suite 1100

San Diego, CA 92121-2133

CUSTOMER NUMBER NO. 28213

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No.: UCSD1480-1	Serial No.: 10/770,885
	Applicants: Hostetler et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: February 2, 2004	Group Art Unit: 1615



U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	AA	MICHAEL BARZA, "Factors Affecting the Intraocular Penetration of Antibiotics: The Influence of Route, Inflammation, Animal Species and Tissue Pigmentation," <i>Scand J. Infect. Dis.</i> , Suppl. 14, pp. 151-159, 1978
	AB	CHENG et al., "Treatment or Prevention of Herpes Simplex Virus Retinitis with Intravitreally Injectable Crystalline 1-O-hexadecylpropanediol-3-phosphoganciclovir" <i>IOVS</i> , Vol. 43, No. 2, pp. 515-521, February 2002
	AC	BISCHOFBERGER et al., "1-[[[(S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] Cytosine, an Intracellular Prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)Cytosine with Improved Therapeutic Index <i>In Vivo</i> " <i>Antimicrob. Agents Chemother.</i> , Vol. 38, No. 10, pp. 2387-2391, October 1994
	AD	DESIDERI et al., "Synthesis and Anti-Rhinovirus Activity of 2-styrylchromones" <i>Antivir. Chem. Chemother.</i> , Vol. 11, pp. 373-381, 2000
	AE	BEADLE et al., "Alkoxyalkyl Esters of Cidofovir and Cyclic Cidofovir Exhibit Multiple-Log Enhancement of Antiviral Activity Against Cytomegalovirus and Herpes Virus Replication <i>in vitro</i> ," <i>Antimicrob. Agents Chemother.</i> , Vol. 46, No. 8, pp. 2381-2386, August 2000
	AF	CHENG et al., "Intravitreal Toxicology in Rabbits of Two Preparations of 1-O-octadecyl-sn glycerol-3-phosphonoformate, a Sustained-Delivery Anti-CMV Drug," <i>Invest Ophthalmol Vis Sci.</i> , Vol. 40, No. 7, pp. 1487-1495, June 1999
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Form 1449

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No.: UCSD1480-1	Serial No.: 10/770,885
	Applicants: Hostetler et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: February 2, 2004	Group Art Unit: 1615

	AG	CHENG et al., "Treatment of herpes retinitis in an animal model with a sustained delivery antiviral drug, liposomal 1-O-octadecyl-SN-glycerol-3- phosphonoformate" <i>Retina</i> , Vol. 19, pp. 325-331, 1999
	AH	LIM et al., "The Role of Gravity in Gentamicin-Induced Toxic Effects in a Rabbit Model," <i>Acrh. Ophthalmol.</i> , Vol. 112, pp. 1363-1367, October 1994
	AI	CHENG et al., "Ganciclovir Release Rates in Vitreous from Different Formulations of 1-O-hexadecylpropanediol-3-phospho-ganciclovir," <i>J. Ocul. Pharmacol. Ther.</i> , Vol. 19, No. 2, 2003
	AJ	CUNDY et al., "Distribution and Metabolism of Intravitreal Cidofovir and Cyclic HPMPC in Rabbits," <i>Curr. Eye Res.</i> , Vol. 15, pp. 569-576, 1996
	AK	ALDERN et al., "Increased Antiviral Activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 Human Lung Fibroblasts is Explained by Unique Cellular Uptake and Metabolism," <i>Mol. Pharmacol.</i> , Vol. 63, No. 3, pp. 678-681, 2003

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Form 1449